Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Estrella Immunopharma, Inc. (ESLA) had Normalized Pre-Tax Income of $-5.54M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.54M |
|
-- |
|
-- |
|
$5.54M |
|
$-5.54M |
|
-- |
|
$-5.54M |
|
|
Normalized Pre-Tax Income |
$-5.54M |
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
$-5.54M |
|
36.17M |
|
36.17M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$1.48M |
|
-- |
|
$1.50M |
|
$2.98M |
|
$9.08M |
|
-- |
|
-- |
|
$9.08M |
|
$-6.09M |
|
$-6.09M |
|
$-6.09M |
|
37.07M |
|
| Cash Flow Statement Financials | |
$-0.88M |
|
-- |
|
$1.28M |
|
$0.92M |
|
$1.32M |
|
$0.40M |
|
$0.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
90.95% |
|
90.95% |
|
-185.98% |
|
90.95% |
|
$-0.16 |
|
$-0.02 |
|
$-0.02 |
|